Company Name	Novogen Limited
Registered Office	Suite 1.02 16-20 Edgeworth David Ave Hornsby, NSW 2077 Australia
Principal Place of Business	Suite 1.02 16-20 Edgeworth David Ave Hornsby, NSW 2077 Australia
Postal Address	PO Box 2333 Hornsby Westfield NSW 1635 Australia
Sector	Biotechnology / Medical / Life Science / Pharmaceutical
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
Principal Activities	Oncology drug research and development
Follow NRT on Social Media
Internet Homepage Address (URL)	http://www.novogen.com
Phone Number	(+612) 9472 4101
Fax Number	(+612) 9476 0388
Mailing address	PO Box 2333 Hornsby Westfield NSW 1635 Australia
Email Address	info@novogen.com
Financial Year End	June 30
Board of Directors	Mr Ian Phillips MNZM (Non-Executive Director, Interim Chairman) [Appointed on 1 July 2015] Mr Iain Ross (Director and Acting CEO) [Appointed on 22 July 2015] Mr John P O'Connor BEC., MAICD (Non-Executive Director, Deputy Chairman) Mr Steven Coffey CA (Non-Executive Director) Professor Peter Gunning B.SC, PH.D (Non-Executive Director) [Effective on 3 March 2014] Mr Bryce Carmine B.SC (Non-Executive Director) [Appointed on 3 June 2015] Dr Graham Kelly BSC, BVSC, PHD (Executive Director, CEO) [Resigned on 22 July 2015] Dr Andrew Heaton BSC, PHD (Executive Director) [Stepped down on 4 March 2014] Robert Birch (Non-Executive Director & Deputy Chairman) [Stepped down on 4 March 2014]
Management Team	Mr Iain Ross (Director and Acting CEO) [Appointed on 22 July 2015] Dr Andrew Heaton BSC, PHD (Vice-President, Drug Discovery) Dr David Brown DIP TECH MGMT, B APP SC, PHD (Chief Scientific Officer) Ms Cristyn Humphreys BBUS(ACC), DIPPOL, FTI, CA (Chief Operating Officer (Administration and Finance)) Dr Justine Stehn BSC, PHD (ATM Program Director) [Appointed on 3 February 2014] Dr Stephen Palmer BSC, PHD (Degenerative Diseases Program Director) Dr Kimberley Lilischkis BSC, PHD, MBA (Clinical & Regulatory Affairs Manager) Ms Kym Robins (Marketing and Communications Manager) Dr Graham Kelly BSC, BVSC, PHD (Executive Director & CEO) [Resigned on 22 July 2015]
Company Secretary	Mr Lionel Mateo
Investor Relations Contact	Ms Cristyn Humphreys (Chief Operating Officer) Ms Kym Robins (Marketing and Communications Manager)
Bankers	Westpac
Auditors	Grant Thornton Auditor Audit Pty Ltd Level 17, 383 Kent Street Sydney, NSW 2000 Australia
Legal Counsel	Addisons Level 12, 60 Carrington Street Sydney, NSW 2000 Australia
Share Registrars	Computershare Investor Services Pty Limited Level 4, 60 Carrington Street, Sydney, Nsw, Australia, 2000 Phone: 1300 787 272
ADR	Novogen Limited's ordinary shares trade in the United States in the form of ADRs on the NASDAQ Capital Market. Each ADR represents twenty-five ordinary Novogen shares. Trading symbol on NASDAQ is 'NVGN'.
ASX Stock Code	NRT
Listing Date	1st September 1994
Ordinary Shares on issue	424m (as of 31 August 2015)
Shares Outstanding	423,116,465 ordinary shares (as of 16 July 2015)
Unlisted Options	117,709,997 unlisted options expiring between 18 November 2015 and 30 December 2015, at different prices varying between $0.125 and $0.30 per option. 61,214,990 unlisted options with a maturity date between 16 December 2019 and 30 June 2020, with an exercise price between $0.15 and $0.40 per option. (as of 28 August 2015)
Total Issued Capital	$124m (as of 16 July 2015)
Capital Raised	$50m (as of 16 July 2015)
Cash and Cash Equivalents	$45m (as of 16 July 2015)
Market Capitalisation	US $110m (AUD $124m) (as of 16 July 2015)
Number of Security holders	ASX : 6,156 NASDAQ : 2,500 (as of 16 July 2015)
Top 20 Shareholders	103,704,668 shares representing 56.61% (as of 16 July 2015)
Year of Inception	1994
Number of Staff	14 (as of 16 July 2015)
ABN	37 063 259 754